The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: Rationale for the use of cytokine shields in allogeneic bone marrow transplantation

Blood

Volumn 95, Issue 9, 2000, Pages 2754-2759

  Hill, Geoffrey R ^b   Ferrara, James L M ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

ALLOGENIC BONE MARROW TRANSPLANTATION; GASTROINTESTINAL TRACT; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; REVIEW;

EID: 0034193057     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.9.2754.009k25_2754_2759     Document Type: Review

References (80)

1. Ferrara JLM, Deeg HJ. Graft versus host disease. N Engl J Med. 1991;324:667.
2. Baker MB, Podack ER, Levy RB. Perforin- and Fas-mediated cytotoxic pathways are not required for allogeneic resistance to bone marrow grafts in mice. Biol Blood Marrow Transplant. 1995;1:69.
3. Baker MB, Altman NH, Podack ER, Levy RB. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med. 1996;183: 2645.
4. van Bekkum DW, Roodenburg J, Heidt PJ, van der Waaij D. Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J Natl Cancer Inst. 1974;52:401.
5. Storb R, Prentice RL, Buckner CD, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings: beneficial effect of a protective environment. N Engl J Med. 1983;308: 302.
6. Moller J, Skirhoj P, Hoiby N, Peterson FB. Protection against graft versus host disease by gut sterilization? Exp Haematol. 1982;10:101.
7. Beelen DW, Haralambie E, Brandt H, et al. Evidence that sustained growth suppression of intestinal anaerobic bacteria reduces the risk of acute graft-versus-host disease after sibling marrow transplantation. Blood. 1992;80:2668.
8. Beelen DW, Elmaagacli A, Muller KD, Hirche H, Schaefer UW. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long term follow-up of an open-label prospective randomized trial. Blood. 1999;93:3267.
9. Antin JH, Weinstein HJ, Guinan EC, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood. 1994;84:1342.
10. Holler E, Kolb HJ, Moller A, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990;75:1011.
11. Holler E, Kolb HJ, Mittermueller J, et al. Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor α (TNF-α) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF-α (MAK 195F). Blood. 1995;86:890.
12. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood. 1994;83:2360.
13. Hill GR, Crawford JM, Cooke KJ, Brinson YS, Pan L, Ferrara JLM. Total body irradiation and acute graft versus host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90:3204.
14. Hill GR, Teshima T, Gerbita A, et al. Differential roles of IL-1 and TNF-α on graft-versus-host disease and graft-versus leukemia. J Clin Invest. 1999;104:459.
15. Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med. 1992; 175:405.
16. Hartmann G, Weiner GJ, Kreig AM. CpG: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci U S A. 1999;6:9305.
17. Scholl PR, Geha RS. MHC class II signaling in B-cell activation. Immunol Today. 1994;9:418.
18. Nestel F, Kichian K, You-Ten K, Desbarats J, Price K, Lapp WS. The role of endotoxin in the pathogenesis of acute graft-versus-host disease. In: Ferrara JLM, Deeg HJ, Burakoff SJ, eds. Graft-vs-Host Disease. 2nd ed. New York: Marcel Dekker; 1997:501.
19. Cooke KR, Hill GR, Crawford JM, et al. TNF-α production to LPS stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest. 1998;102: 1882.
20. Nash A, Pepe MS, Storb R, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood. 1992;80:1838.
21. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood. 1990;76:1867.
22. Clift RA, Buckner CD, Thomas WI, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood. 1994;84:2036.
23. Deeg HJ, Spitzer TR, Cottler-Fox M, Cahill R, Pickle LW. Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis. Bone Marrow Transplant. 1991;7:193.
24. Hattori K, Hirano T, Miyajima H, et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood. 1998;91:4051.
25. Piguet PF, Grau GE, Allet B, Vassalli PJ. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J Exp Med. 1987;166:1280.
26. Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood. 1992;80:2964.
27. Braun YM, Lowin B, French L, Acha-Orbea H, Tschopp J. Cytotoxic T cells deficient in both functional Fas ligand and pertorin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med. 1996;183:657.
28. Graubert TA, Russell JH, Ley T. The role of granzyme B in murine models of acute graft-versus-host disease and graft rejection. Blood. 1996;87: 1232.
29. Mowat A. Intestinal Graft versus Host Disease. In: Ferrara JLM, Deeg HJ, Burakoff SJ, eds. Graft-vs-Host Disease. 2nd ed. New York: Marcel Dekker; 1997:337.
30. Garside P, Reid S, Steel M, Mowat AM. Differential cytokine production associated with distinct phases of murine graft-versus-host reaction. Immunology. 1994;82:211.
31. Madara JL, Stafford J. Interferon-γ directly affects barrier function of cultured intestinal epithelial monolayers. J Clin Invest. 1989;83:724.
32. Garside P, Bunce C, Tomlinson RC, Nichois BL, Mowat AM. Analysis of the enteropathic effects of tumour necrosis factor α. Cytokine. 1994;5:24.
33. Mowat AM, Hutton AK, Garside P, Steel MA. A role for IL-1α in immunologically mediated enteropathy. Immunology. 1993;80:110.
34. Mowat A. Antibodies to IFN-gamma prevent immunological mediated intestinal damage in murine graft-versus-host reactions. Immunology. 1989;68:18.
35. Garside P, Hutton AK, Severn A, Liew FY, Mowat AM. Nitric oxide mediates intestinal pathology in graft-vs-host disease. Eur J Immunol. 1992;22: 2141.
36. Thiele DL, Eigenbrodt ML, Bryde SE, Eigenbrodt EH, Lipsky PE. Intestinal graft-versus-host disease is initiated by donor T cells distinct from classic cytotoxic T lymphocytes. J Clin Invest. 1989;84:1947.
37. Lin T, Brunner T, Tietz B, et al. Fas-ligand mediated killing by intestinal intraepithelial lymphocytes: participation in intestinal graft-versus-host disease. J Clin Invest. 1998;101:570.
38. Jackson SK, Parton J, Barnes RA, Poynton CH, Fegan C. Effect of IgM-enriched intravenous immunoglobulin (pentaglobulin) on endotoxaemia and anti-endotoxin antibodies in bone marrow transplantation. Eur J Clin Invest. 1993;23:540.
39. Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning CJ. Peptidoglycan-and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem. 1999;274:17,406.
40. Cowdery JS, Chace JH, Yi AK, Krieg AM. Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J Immunol. 1996;156:4570.
41. Retzlaff C, Yamamato Y, Hoffman PS, Freidman H, Klein TW. Bacterial heat shock proteins directly induce cytokine mRNA and interleukin-1 secretion in macrophage cultures. Infect Immunol. 1994;62:5689.
42. Lichtman A, Krenger W, Ferrara JLM. Cytokine Networks: In: Ferrara JLM, Deeg HJ, Burakoff SJ, eds. Graft-Versus-Host Disease. 2nd ed. New York: Marcel Dekker; 1997:179.
43. Truitt RL, Atasoylu AA. Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation. Blood. 1991;77:2515.
44. Truitt RL, Johnson BD, McCabe C, Weiler MB. Graft versus leukemia. In: Ferrara JLM, Deeg HJ, Burakoff SJ, eds. Graft-vs-Host Disease. 2nd ed. New York: Marcel Dekker; 1997:385.
45. Teshima T, Hill GR, Pan L, et al. Interleukin-11 improves separate graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. J Clin Invest. 1999; 104:317.
46. Pan L, Teshima T, Hill GR, et al. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease. Blood. 1999;93:4071.
47. Tsukada N, Kobata T, Aivawa Y, Yagita H, Okumura K. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of bone marrow transplantation. Blood. 1999;93:2738.
48. Du X, Williams DA. Interleukin IL-11: review of molecular, cell biology, and clinical use. Blood. 1997;11:3897.
49. Du XX, Neben T, Goldman S, Williams DA. Effects of recombinant human interleukin-11 on hematopoietic reconstitution in transplant mice: acceleration of recovery of peripheral blood neutrophils and platelets. Blood. 1993;81:27.
50. Teicher BA, Chen YN, Ara G, et al. Interaction of interleukin-11 with cytotoxic therapies in vitro against CEM cells and in vivo against EMT-6 murine mammary carcinoma. Int J Cancer. 1996; 67:864.
51. Maze R, Moritz T, Williams DA. Increased survival and multilineage hematopoietic protection from delayed and severe myelosuppressive effects of a nitrosourea with recombinant interleukin-11. Cancer Res. 1994;54:4947.
52. Trepicchio WL, Bozza M, Pedneault G, Dorner AJ. Recombinant human IL-11 attenuates the inflammatory response through down regulation of proinflammatory cytokine release and nitric oxide production. J Immunol. 1996;157:3627.
53. Trepicchio WL, Wang L, Bozza M, Dorner AJ. Interleukin-11 regulates macrophage effector function through the inhibition of NF-kB. J Immunol. 1997;159:5661.
54. Waxman AB, Einarsson O, Seres T, et al. Targeted lung expression of interleukin-11 enhances murine tolerance of 100% oxygen and diminishes hyperoxia-induced DNA fragmentation. J Clin Invest. 1999;101:1970.
55. Redlich CA, Gao X, Rockwell S, Kelley M, Elias JA. IL-11 enhances survival and decreases TNF production after radiation-induced thoracic injury. J Immunol. 1996;157:1705.
56. Qui BS, Pfieffer CJ, Keith JC. Protection by recombinant interleukin-11 against experimental TNB-induced colitis. Dig Dis Sci. 1996;41:1625.
57. Opal SM, Jhung JW, Keith JCJ, Goldman SJ, Palardy JE, Parejo NA. Additive effects of human recombinant interleukin-11 and granulocyte colony-stimulating factor in experimental gram-negative sepsis. Blood. 1999;93:3467.
58. Leng SX, Elias JA. Interleukin-11 inhibits macrophage interleukin-12 production. J Immunol. 1997;159:2161.
59. Du XX, Doerschuk CM, Orazi A, Williams DA. A bone marrow stromal-derived growth factor, interleukin-11, stimulates recovery of small intestinal mucosal cells after cytoablative therapy. Blood. 1994;83:33.
60. Potten CS. Protection of the small intestinal clonogenic stem cells from radiation-induced damage by pretreatment with interleukin 11 also increases murine survival time. Int J Cancer. 1996; 14:452.
61. Keith JC, Albert L, Sonis ST, Pfeiffer CJ, Schaub RG. IL-11, apleotropic cytokine: exciting new effects of IL-11 on gastrointestinal mucosal biology. Stem Cells. 1994;12:79.
62. Orazi A, Du X, Yang Z, Kashai M, Williams DA. Interleukin-11 prevents apoptosis and accelerates recovery of small intestinal mucosa in mice treated with combined chemotherapy and radiation. Lab Invest. 1996;75:33.
63. Sonis S, Muska A, O'Brien J, Van Vugt A, Langer-Safer P, Keith J. Alteration in the frequency, severity and duration of chemotherapy-induced mucositis in hamsters by IL-11. Eur J Cancer. 1995; 31B:261.
64. Liu Q, Du XX, Schindel DT, et al. Trophic effects of IL-11 in rats with experimental short bowel syndrome. J Pediatr Surg. 1996;31:1047.
65. Fiore NF, Ledniczky G, Liu Q, et al. Comparison of interleukin-11 and epidermal growth factor on residual small intestine after massive small bowel resection. J Pediatr Surg. 1999;33:24.
66. Du X, Liu O, Yang Z, et al. Protective effects of interleukin-11 in a murine model of ischemic bowel necrosis. Am J Physiol. 1997;272:G545.
67. Hill GR, Cooke KR, Teshima T, et al. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest. 1998; 102:115.
68. Housley R, Morris C, Boyle W, et al. Keratinocyte growth factor induces proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal tract. J Clin Invest. 1994;94:1764.
69. Pierce G, Yanagihara D, Klopchin K, et al. Stimulation of all epithelial elements during skin regeneration by keratinocyte growth factor. J Exp Med. 1994;179:831.
70. Panos R, Rubin J, Aaronson S, Mason R. Keratinocyte growth factor/scatter factor are heparin-binding growth factors for alveolar type II cells in fibroblast-conditioned medium. J Clin Invest. 1993;92:969.
71. Ulich T, Yi E, Cardiff R, et al. Keratinocyte growth factor is a growth factor for mammary epithelium in vivo. Am J Pathol. 1994;144:862.
72. Yi E, Shabaik A, Lacey D, et al. Keratinocyte growth factor causes proliferation of urothelium in vivo. J Urol. 1995;154:1566.
73. Farrell C, Bready J, Rex K, et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res. 1998;58:933.
74. Khan WB, Shui C, Ning S, Knox SJ. Enhancement of murine intestinal stem cell survival after irradiation by keratinocyte growth factor. Radiat Res. 1997;148:248.
75. Frank S, Muna B, Werner S. The human homologue of a bovine-none-selenium glutathione peroxidase is a novel keratinocyte growth factor-regulated gene. Oncogene. 1997;14:915.
76. Takeoka M, Ward W, Pollack H, Kamp D, Panos R. KGF facilitates repair of radiation-induced DNA damage in alveolar epithelial cells. Am J Physiol. 1997;27:L1174.
77. Krijanovski OI, Hill GR, Cooke KR, Teshima T, Brinson YS, Ferrara JLM. Keratinocyte growth factor (KGF) separates graft-versus-leukemia effects from graft-versus-host disease. Blood. 1999;94:825.
78. Panoskaltsis-Mortari A, Lacey DL, Vallera DA, Blazer BR. Keralinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood. 1998;92:3960.
79. Serdar C, Heard R, Prathikanti D, et al. Safety, pharmacokinetics and biologic activity of rHuKGF in normal volunteers: results of a placebo-controlled randomized double-blind phase 1 study [abstract]. Blood. 1997;90(suppl 1):172a.
80. Adkins D, Brown R, Khoury H, et al. Low-intensity conditioning regimen for related donor allogeneic peripheral blood stem cell (PBSC) transplant using low-dose (550 cGy) high dose rate (30 cGy/ min) single-exposure total body irradiation (TBI) [abstract]. Blood. 1998;92:138a.